News Sentiment

PCVX sentiment intelligence

Vaxcyte Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 58.21 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

86/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-0.3% over one week, +22.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Vaxcyte (NASDAQ: PCVX) adds independent director John Markels, sets $430,000 equity grant

Market Reaction

Balanced read

55/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 86/100 classification
One-week reaction -0.3% Price digesting
Trend fit Trend inactive 22.7% over four weeks
Fair value -4.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 40
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 9
Simply Wall Street 4
simplywall.st 4
DirectorsTalk Interviews 3
Finviz 3
www.marketscreener.com 3
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 13
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stock Titan Direct company coverage

Vaxcyte (NASDAQ: PCVX) adds independent director John Markels, sets $430,000 equity grant

Vaxcyte, Inc. announced the retirement of director Heath Lukatch and the appointment of John Markels as a new independent Class II director, effective July 16, 2026. Markels will join the Audit and Compensation Committees and receive compensation, including an annual equity grant

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:13
Source
Stock Titan
DirectorsTalk Interviews Direct company coverage

Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring an 87% Upside Potential in the Biotech Sector

Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology company with a strong vaccine pipeline, including VAX-24, and an impressive market capitalization of $8.41 billion. Despite being in a pre-revenue stage with a net loss, analysts see significant potential, with an average tar

Tone
Positive 70/100
Event
Market update
Published
13 Jul 2026 09:41
Source
DirectorsTalk Interviews
Investing News Network Direct company coverage

Vaxcyte to Participate in Upcoming Investor Conferences

Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in two upcoming investor conferences in July 2026: the Leerink Partners Therapeutics Forum and the BTIG Virtual Biotechnology Conference. Company management will host one-on-one meetings at both events. Vaxcyte is a clinica

Tone
Positive 62/100
Event
Market update
Published
09 Jul 2026 20:09
Source
Investing News Network
Stock Traders Daily Direct company coverage

Why (PCVX) Price Action Is Critical for Tactical Trading

This article analyzes Vaxcyte Inc. (NASDAQ: PCVX) price action, indicating strong sentiment across all horizons and presenting three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It highlights a significant risk-reward short setu

Tone
Positive 75/100
Event
Market update
Published
09 Jul 2026 07:44
Source
Stock Traders Daily
Simply Wall Street Direct company coverage

Should Early VAX-A1 Trial Progress Require Action From Vaxcyte (PCVX) Investors?

Vaxcyte recently announced progress in its early-stage clinical trial for VAX-A1, a Group A streptococcus vaccine candidate. While this introduces a new potential market, the primary focus for investors remains the VAX-31 pneumococcal vaccine pipeline and managing cash burn. The

Tone
Positive 63/100
Event
Balance sheet
Published
07 Jul 2026 09:11
Source
Simply Wall Street
Investing.com Direct company coverage

Vaxcyte president and CFO sells $572k in company stock

Andrew Guggenhime, President and CFO of Vaxcyte, Inc. (NASDAQ:PCVX), sold 10,000 shares of company stock for approximately $572,836 on July 6, 2026. These sales, executed under a Rule 10b5-1 trading plan, occurred after Guggenhime exercised stock options for the same number of sh

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 07:39
Source
Investing.com
Investing.com South Africa Direct company coverage

Vaxcyte president and CFO sells $572k in company stock By Investing.com

Andrew Guggenhime, President and CFO of Vaxcyte (NASDAQ:PCVX), sold 10,000 shares of company stock for approximately $572,836 on July 6, 2026. These sales were part of a Rule 10b5-1 plan, following his exercise of stock options. Vaxcyte stock has seen a 71% return over the past y

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 00:09
Source
Investing.com South Africa
Investing.com Canada Direct company coverage

Form 4 Vaxcyte Inc For: 6 July By Investing.com

This article reports a Form 4 filing for Vaxcyte Inc, dated July 6th. The content is brief, primarily serving as an announcement of the filing by Investing.com. It mentions the stock symbol PCVX with a reported -2.45% change.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 23:09
Source
Investing.com Canada
Stock Titan Direct company coverage

[Form 4] Vaxcyte, Inc. Insider Trading Activity

Vaxcyte, Inc.'s President and CFO, Andrew Guggenhime, reported an insider trading activity where he exercised stock options to acquire 10,000 shares at $5.35 per share, and subsequently sold all 10,000 shares in two open-market transactions. These sales, executed under a Rule 10b

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Affiliate plans 10,000-share sale by option exercise — PCVX

An affiliate of Vaxcyte, Inc. (PCVX) has filed a Form 144 to report a proposed sale of 10,000 common shares through the exercise of stock options on July 6, 2026. The filing also indicates a prior sale of 10,000 common shares for $530,000 on June 18, 2026. The proposed sale is va

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:10
Source
Stock Titan
Simply Wall Street Direct company coverage

PCVX - Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity

Vaxcyte (PCVX) is positioned for long-term growth due to its late-stage vaccine programs, particularly VAX-31 and VAX-A1, and expanded manufacturing capabilities. Analysts project significant revenue growth by 2029, with a consensus price target of $109, implying the stock is cur

Tone
Positive 75/100
Event
Earnings
Published
05 Jul 2026 06:39
Source
Simply Wall Street
Finviz Direct company coverage

PCVX - Vaxcyte Inc Volatility & Greeks

This article provides a detailed financial overview of Vaxcyte Inc (PCVX), including its stock performance, volatility metrics, and various financial ratios up to July 2nd. It highlights key data such as market capitalization, income, sales, EPS, insider and institutional ownersh

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 19:10
Source
Finviz
Finviz Direct company coverage

PCVX - Vaxcyte Inc Options

The article provides comprehensive financial data and trading information for Vaxcyte Inc (PCVX), including its last close price, market capitalization, earnings per share, sales figures, and various performance metrics. It also details insider and institutional ownership, short

Tone
Positive 60/100
Event
Earnings
Published
04 Jul 2026 06:09
Source
Finviz
Ad-hoc-news.de Direct company coverage

Vaxcyte stock stays tied to pipeline progress. Nasdaq listing and SEC filings frame the setup.

Vaxcyte's stock performance is primarily driven by its pneumococcal vaccine pipeline, clinical milestones, and company disclosures. The company, a US-listed vaccine developer on Nasdaq, has its investor relations information as the main public reference point. Its market valuatio

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 15:40
Source
Ad-hoc-news.de
Finviz Direct company coverage

PCVX - Vaxcyte Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial data for Vaxcyte Inc (PCVX). It details various financial metrics, including market capitalization, income, sales, EPS, P/E ratios, and stock performance, alongside insider and institutional ownership statis

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 05:40
Source
Finviz
Simply Wall Street Direct company coverage

Have Insiders Sold Vaxcyte Shares Recently?

A recent insider transaction at Vaxcyte (NASDAQ:PCVX) involved Co-Founder Grant Pickering selling US$1.3m worth of shares at an average price of US$55.22, reducing his holding by 5.4%. This was the largest insider sale in the last year, occurring near the current share price of U

Tone
Negative 35/100
Event
Market update
Published
02 Jul 2026 15:40
Source
Simply Wall Street
Investing.com UK Direct company coverage

Form 144 Vaxcyte For: 1 July By Investing.com

The article announces the filing of Form 144 for Vaxcyte on July 1st. It also features current market data for indices, commodities, bonds, and shares, along with trending news and top stock movers, including Vaxcyte's stock performance.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:56
Source
Investing.com UK
Stock Titan Direct company coverage

PCVX (NASDAQ) director reported three 2,250-share sales and RSU/option items

A recently filed Form 144 from Vaxcyte, Inc. (PCVX) indicates that director James Wassil completed three sales of 2,250 shares each on April 1, May 1, and June 1, 2026, generating gross proceeds of $131,475.60, $127,870.65, and $111,416.62 respectively. The filing also details up

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell Small Cap Comp Growth Benchmark

Vaxcyte, Inc. (NasdaqGS: PCVX) has been added to the Russell Small Cap Comp Growth Benchmark. This news follows a series of recent developments for the company, including board changes, insider stock sales, and progress in its vaccine trials for various bacterial diseases. The co

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 20:10
Source
www.marketscreener.com
TradingView Direct company coverage

Price to earnings forward of Vaxcyte, Inc. – NASDAQ:PCVX

This page from TradingView provides financial information for Vaxcyte, Inc. (NASDAQ: PCVX), specifically focusing on its forward price-to-earnings ratio. The content is part of a larger financial data and trading platform.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 18:42
Source
TradingView
Benzinga Direct company coverage

10 Health Care Stocks With Whale Alerts In Today’s Session

This article highlights unusual options activity, known as "whale alerts," for ten health care stocks. It details bullish, bearish, and neutral sentiment trades on specific call and put contracts for companies like Vaxcyte, SELLAS Life Sciences, Hims & Hers Health, and others. Th

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 17:40
Source
Benzinga
www.marketscreener.com Direct company coverage

Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell 2000 Growth Benchmark

Vaxcyte, Inc. (NasdaqGS: PCVX), a clinical-stage vaccine company, has been added to the Russell 2000 Growth Benchmark. The company is focused on engineering high-fidelity vaccines to combat bacterial diseases, with a pipeline that includes candidates for pneumonia and Group A Str

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 10:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing

An insider at Vaxcyte, Inc. recently sold shares totaling $1,338,270, as reported in a new SEC filing. This transaction occurred on June 29, 2026, and follows a previous insider share sale on June 22, 2026. Vaxcyte is a clinical-stage vaccine company developing high-fidelity vacc

Tone
Negative 30/100
Event
Market update
Published
29 Jun 2026 07:40
Source
www.marketscreener.com
Simply Wall Street Direct company coverage

Is Vaxcyte’s (PCVX) Russell Index Debut Quietly Reframing Its Long‑Term Governance And Growth Story?

Vaxcyte (PCVX) was recently added to several Russell growth indices and refreshed its board, with Moncef Slaoui joining as an independent director and Jacks Lee transitioning to a manufacturing consultant role. While these moves are positive for profile and governance, the primar

Tone
Positive 68/100
Event
Market update
Published
29 Jun 2026 01:11
Source
Simply Wall Street